<table-wrap xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="table3" position="float"><object-id pub-id-type="doi">10.7554/eLife.28020.005</object-id><label>Table 3.</label><caption><title>Antiviral activity of GRL-121 and &#8722;142 against highly PI-resistant HIV-1 variants.</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="bottom"/><th/><th colspan="5">Mean IC<sub>50</sub> in nM&#160;&#177;&#160;SD (fold-change)</th></tr><tr><th>Virus species</th><th/><th>LPV</th><th>ATV</th><th>DRV</th><th>GRL-121</th><th>GRL-142</th></tr></thead><tbody><tr><td valign="bottom">Wild-type</td><td>cHIV<sub>NL4-3</sub><sup>WT</sup></td><td>13&#160;&#177;&#160;2</td><td>4.0&#160;&#177;&#160;2.3</td><td>3.2&#160;&#177;&#160;0.7</td><td>0.26&#160;&#177;&#160;0.05</td><td>0.019&#160;&#177;&#160;0.017</td></tr><tr><td valign="bottom"><sub>invitro</sub>HIV<sub>PI</sub><sup>R</sup>*</td><td>HIV<sub>SQV-5&#956;M</sub></td><td>&gt;1000 (&gt;77)</td><td>430&#160;&#177;&#160;20 (108)</td><td>17&#160;&#177;&#160;7 (5)</td><td>0.026&#160;&#177;&#160;0.01 (0.1)</td><td>0.00018&#160;&#177;&#160;0.00003 (0.009)</td></tr><tr><td valign="bottom"/><td>HIV<sub>APV-5&#956;M</sub></td><td>280&#160;&#177;&#160;15 (22)</td><td>3.0&#160;&#177;&#160;1.0 (1)</td><td>39&#160;&#177;&#160;16 (12)</td><td>0.13&#160;&#177;&#160;0.08 (0.5)</td><td>0.0000085&#160;&#177;&#160;0.000008 (0.0004)</td></tr><tr><td valign="bottom"/><td>HIV<sub>LPV-5&#956;M</sub></td><td>&gt;1000 (&gt;77)</td><td>46&#160;&#177;&#160;10 (12)</td><td>280&#160;&#177;&#160;50 (86)</td><td>0.0018&#160;&#177;&#160;0.0006 (0.007)</td><td>0.0000019&#160;&#177;&#160;0.0000014 (0.0001)</td></tr><tr><td valign="bottom"/><td>HIV<sub>IDV-5&#956;M</sub></td><td>250&#160;&#177;&#160;15 (19)</td><td>56&#160;&#177;&#160;9 (14)</td><td>37&#160;&#177;&#160;8 (12)</td><td>0.0092&#160;&#177;&#160;0.0163 (0.04)</td><td>0.00018&#160;&#177;&#160;0.00028 (0.009)</td></tr><tr><td valign="bottom"/><td>HIV<sub>NFV-5&#956;M</sub></td><td>37&#160;&#177;&#160;3 (3)</td><td>12&#160;&#177;&#160;2 (3)</td><td>7.7&#160;&#177;&#160;3 (2)</td><td>0.048&#160;&#177;&#160;0.018 (0.2)</td><td>0.00024&#160;&#177;&#160;0.00026 (0.01)</td></tr><tr><td valign="bottom"/><td>HIV<sub>ATV-5&#956;M</sub></td><td>310&#160;&#177;&#160;20 (24)</td><td>&gt;1000 (&gt;250)</td><td>25&#160;&#177;&#160;1 (8)</td><td>0.092&#160;&#177;&#160;0.097 (0.4)</td><td>0.015&#160;&#177;&#160;0.004 (0.8)</td></tr><tr><td valign="bottom"/><td>HIV<sub>TPV-15&#956;M</sub></td><td>&gt;1000 (&gt;77)</td><td>&gt;1000 (&gt;250)</td><td>40&#160;&#177;&#160;3 (13)</td><td>0.063&#160;&#177;&#160;0.016 (0.2)</td><td>0.00024&#160;&#177;&#160;0.00007 (0.01)</td></tr><tr><td valign="bottom"><sub>rCL</sub>HIV**</td><td><sub>rCL</sub>HIV<sub>F16</sub></td><td>&gt;1000 (&gt;77)</td><td>193&#160;&#177;&#160;23 (48)</td><td>3357&#160;&#177;&#160;600 (1,049)</td><td>2.5&#160;&#177;&#160;0.9 (10)</td><td>0.016&#160;&#177;&#160;0.016 (0.8)</td></tr><tr><td valign="bottom"/><td><sub>rCL</sub>HIV<sub>F39</sub></td><td>&gt;1000 (&gt;77)</td><td>374&#160;&#177;&#160;23 (94)</td><td>313&#160;&#177;&#160;230 (98)</td><td>0.028&#160;&#177;&#160;0.02 (0.1)</td><td>0.0061&#160;&#177;&#160;0.002 (0.3)</td></tr><tr><td valign="bottom"/><td><sub>rCL</sub>HIV<sub>V42</sub></td><td>&gt;1000 (&gt;77)</td><td>270&#160;&#177;&#160;20 (68)</td><td>343&#160;&#177;&#160;28 (107)</td><td>3.1&#160;&#177;&#160;1.9 (12)</td><td>0.026&#160;&#177;&#160;0.023 (1)</td></tr><tr><td valign="bottom"/><td><sub>rCL</sub>HIV<sub>T44</sub></td><td>&gt;1000 (&gt;77)</td><td>&gt;1000 (&gt;250)</td><td>2487&#160;&#177;&#160;210 (777)</td><td>12&#160;&#177;&#160;6 (46)</td><td>0.69&#160;&#177;&#160;0.66 (36)</td></tr><tr><td valign="bottom"/><td><sub>rCL</sub>HIV<sub>M45</sub></td><td>&gt;1000 (&gt;77)</td><td>&gt;1000 (&gt;250)</td><td>1924&#160;&#177;&#160;1570 (601)</td><td>3.8&#160;&#177;&#160;0.5 (15)</td><td>0.094&#160;&#177;&#160;0.113 (5)</td></tr><tr><td valign="bottom"/><td><sub>rCL</sub>HIV<sub>T48</sub></td><td>&gt;1000 (&gt;77)</td><td>440&#160;&#177;&#160;26 (110)</td><td>315&#160;&#177;&#160;61 (98)</td><td>1.1&#160;&#177;&#160;1.1 (4)</td><td>0.0052&#160;&#177;&#160;0.0017 (0.3)</td></tr></tbody></table><table-wrap-foot><fn><p>*<sub>invitro</sub>HIV<sub>PI</sub><sup>R</sup>, in vitro PI-selected HIV-1 variants; **<sub>rCL</sub>HIV, recombinant clinical HIV-1 variants.</p><p>Numbers in parentheses represent fold changes in IC<sub>50</sub>s for each isolate compared to the IC<sub>50</sub>s for wild-type cHIV<sub>NL4-3</sub><sup>WT</sup>. All assays were conducted in triplicate, and the data shown represent mean values (&#177;1 standard deviation) derived from the results of at least three independent experiments.</p></fn></table-wrap-foot></table-wrap>